Literature DB >> 20543091

Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats.

Péter Bencsik1, Krisztina Kupai, Zoltán Giricz, Anikó Görbe, Judit Pipis, Zsolt Murlasits, Gabriella F Kocsis, Zoltán Varga-Orvos, László G Puskás, Csaba Csonka, Tamás Csont, Péter Ferdinandy.   

Abstract

We have previously shown that the inhibition of myocardial nitric oxide (NO) and peroxynitrite-matrix metalloproteinase (MMP) signaling by early preconditioning (PC) is involved in its cardioprotective effect. Therefore, in the present study, we investigated the role of NO and peroxynitrite-MMP signaling in the development of late PC. PC was performed by five consecutive cycles of 4-min coronary occlusion and 4-min reperfusion in anesthetized rats in vivo. Twenty-four hours later, hearts were subjected to a 30-min coronary occlusion followed by 180-min reperfusion to measure infarct size. In separate experiments, heart tissue was sampled to measure biochemical parameters before and 3, 6, 12, or 24 h after the PC protocol, respectively. Late PC decreased infarct size, increased cardiac inducible NO synthase (iNOS) activity and gene expression, and decreased SOD activity at 24 h significantly compared with sham-operated controls. Late PC increased cardiac superoxide levels significantly at 24 h; however, it did not change cardiac NO levels. Cardiac peroxynitrite levels were significantly decreased. Downstream cellular targets of peroxynitrite, MMP-2 and MMP-9 activities were decreased in the late PC group at 24 h compared with the sham-operated group. To verify if PC-induced inhibition of MMPs had a causative role in the reduction of infarct size, in separate experiments, we measured infarct size after the pharmacological inhibition of MMPs by ilomastat and found a significant reduction of infarct size compared with the vehicle-treated group. In conclusion, this is the first demonstration that the inhibition of cardiac peroxynitrite-MMP signaling contributes to cardioprotection by late PC and that pharmacological inhibition of MMPs is able to reduce infarct size in vivo. Furthermore, increased expression of iNOS may play a role in the development of late PC; however, increased iNOS activity does not lead to increased NO production in late PC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543091     DOI: 10.1152/ajpheart.00052.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  13 in total

1.  Specific Mechanisms Underlying Right Heart Failure: The Missing Upregulation of Superoxide Dismutase-2 and Its Decisive Role in Antioxidative Defense.

Authors:  Rolf Schreckenberg; Manuel Rebelo; Alexander Deten; Martin Weber; Susanne Rohrbach; Márton Pipicz; Csaba Csonka; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  Antioxid Redox Signal       Date:  2015-06-18       Impact factor: 8.401

2.  Acute and chronic cardioprotection by the enkephalin analogue, Eribis peptide 94, is mediated via activation of nitric oxide synthase and adenosine triphosphate-regulated potassium channels.

Authors:  Garrett J Gross; Anna Hsu; Kasem Nithipatikom; Adam W Pfeiffer; Irina Bobrova; Erik Bissessar
Journal:  Pharmacology       Date:  2012-07-18       Impact factor: 2.547

3.  The role of hypoxia-inducible factor-1α and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levosimendan in rat cardiomyocytes.

Authors:  Andreas Goetzenich; Nima Hatam; Stephanie Preuss; Ajay Moza; Christian Bleilevens; Anna B Roehl; Rüdiger Autschbach; Jürgen Bernhagen; Christian Stoppe
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18

Review 4.  The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.

Authors:  Ioanna Andreadou; Efstathios K Iliodromitis; Tienush Rassaf; Rainer Schulz; Andreas Papapetropoulos; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-09-23       Impact factor: 8.739

5.  Preemptive conditioning of the swine heart by H11 kinase/Hsp22 provides cardiac protection through inducible nitric oxide synthase.

Authors:  Li Chen; Paulo Lizano; Xin Zhao; Xiangzhen Sui; Sunil K Dhar; You-Tang Shen; Dorothy E Vatner; Stephen F Vatner; Christophe Depre
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-11       Impact factor: 4.733

6.  Periosteal microcirculatory reactions in a zoledronate-induced osteonecrosis model of the jaw in rats.

Authors:  Ágnes Janovszky; Andrea Szabó; Renáta Varga; Dénes Garab; Mihály Boros; Csilla Mester; Nikolett Beretka; Tamás Zombori; Hans-Peter Wiesmann; Ricardo Bernhardt; Imre Ocsovszki; Péter Balázs; József Piffkó
Journal:  Clin Oral Investig       Date:  2014-10-30       Impact factor: 3.573

7.  Cardiac ischemia and ischemia/reperfusion cause wide proteolysis of the coronary endothelial luminal membrane: possible dysfunctions.

Authors:  Blanca Arroyo-Flores; Erika Chi-Ahumada; Erika Briones-Cerecero; Alma Barajas-Espinosa; Sandra Perez-Aguilar; Ana Barba de la Rosa; Maureen Knabb; Rafael Rubio
Journal:  Open Cardiovasc Med J       Date:  2011-12-30

8.  Targeting Mitochondrial Dysfunction with L-Alpha Glycerylphosphorylcholine.

Authors:  Gerda Strifler; Eszter Tuboly; Anikó Görbe; Mihály Boros; Daniella Pécz; Petra Hartmann
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  Adverse Effects on β-Adrenergic Receptor Coupling: Ischemic Postconditioning Failed to Preserve Long-Term Cardiac Function.

Authors:  Rolf Schreckenberg; Péter Bencsik; Martin Weber; Yaser Abdallah; Csaba Csonka; Kamilla Gömöri; Krisztina Kiss; János Pálóczi; Judit Pipis; Márta Sárközy; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  J Am Heart Assoc       Date:  2017-12-22       Impact factor: 5.501

10.  Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection.

Authors:  Péter Bencsik; Krisztina Kupai; Anikó Görbe; Éva Kenyeres; Zoltán V Varga; János Pálóczi; Renáta Gáspár; László Kovács; Lutz Weber; Ferenc Takács; István Hajdú; Gabriella Fabó; Sándor Cseh; László Barna; Tamás Csont; Csaba Csonka; György Dormán; Péter Ferdinandy
Journal:  Front Pharmacol       Date:  2018-04-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.